SCHEMBL9892691

SCHEMBL9892691

NC(=O)Cc1cc(C(F)(F)F)ccc1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 4/20 0.50
PSEN1 P49768 1/20 0.47
PSEN2 P49810 1/20 0.47
APH1B Q8WW43 1/20 0.47
NCSTN Q92542 1/20 0.47
APH1A Q96BI3 1/20 0.47
PSENEN Q9NZ42 1/20 0.47
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
RXRG P48443 1/20 0.46
BACE1 P56817 1/20 0.45
ICMT O60725 4/20 0.44
FABP4 P15090 2/20 0.43
TACR1 P25103 3/20 0.42
ALDH1A1 P00352 1/20 0.42
FABP5 Q01469 1/20 0.42
POLQ O75417 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9892688 0.88 PTGDR2 (0.53) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL9892653 0.88 PSEN1 (0.56) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL9892692 0.86 ICMT (0.53) PTGDR2ICMT
SCHEMBL9892683 0.86 PTGDR2 (0.51) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL9890734 0.82 FFAR1 (0.49) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL9892679 0.82 PTGDR2 (0.47) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL9890776 0.81 PSEN1 (0.49) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2391627 0.81 RORB (0.51) ICMTALDH1A1
SCHEMBL27682241 0.81 PTGDR2 (0.50) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL2391307 0.80 FFAR1 (0.49) PTGDR2ICMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGDR2 1062/4885PSEN1 2126/4885PSEN2 1867/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGDR2 1062/4885PSEN1 2126/4885PSEN2 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.